N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
C.R.C. Beatson Laboratories, Glasgow, Scotland, United Kingdom
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
University of Illinois at Chicago, Chicago, Illinois, United States
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Washington University Barnard Cancer Center, Saint Louis, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.